X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Nicardipine Hydrochloride Capsules is a calcium channel blocker indicated for the short-term treatment of hypertension when oral therapy is not feasible.
Lead Product(s): Nicardipine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nicardipine Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 25, 2023
Details:
Nicardipine Hydrochloride Capsules, 20 mg and 30 mg, is the generic version of Cardene®1 Capsules, 20 mg and 30 mg, of Chiesi USA, Inc. Nicardipine Hydrochloride capsules, will be distributed in the U.S. by Glenmark Pharmaceuticals Inc., USA.
Lead Product(s): Nicardipine Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Nicardipine Hydrochloride-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
H-100 (nicardipine), a novel, patented, non-invasive topical treatment being developed for Peyronie’s disease, is being developed as a topical gel using nanotechnology to potentially enhance permeation of the medication.
Lead Product(s): Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area: Dermatology Product Name: H100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 03, 2022
Details:
H-100 may be able to provide the first-ever non-invasive treatment to a confounding and often painful condition for which there have been few viable solutions. As a topical, H-100 has the potential to be approved as the first non-invasive treatment for the condition.
Lead Product(s): Nicardipine Hydrochloride,Superoxide Dismutase,Emu oil
Therapeutic Area: Dermatology Product Name: H100
Highest Development Status: Phase IProduct Type: Small molecule
Partner/Sponsor/Collaborator: Hybrid Medical
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
